Thi Thu Ha Nguyen

Thi Thu Ha Nguyen

Auto-generated profile, based on publicly available information

Thi Thu Ha Nguyen

Inserm, Gustave Roussy, Centre de recherche en épidémiologie et santé des populations (CESP) Université Paris‐Saclay (UVSQ) Villejuif France

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2020 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
ARAlexis Revet
Alexis Revet
FMFrançois Montastruc
François Montastruc
ARAnne Roussin
Anne Roussin
JRJean-Philippe Raynaud
Jean-Philippe Raynaud
MLMaryse Lapeyre-Mestre
Maryse Lapeyre-Mestre
TNThi Thu Ha Nguyen
Thi Thu Ha Nguyen
Background: Antidepressants-induced movement disorders are rare and imperfectly known adverse drug reactions. The risk may differ between different antidepressants and antidepressants’ classes. The objective of this study was to assess the putative association of each antidepressant and antidepressants’ classes with movement disorders. Methods: Using VigiBase®, the WHO Pharmacovigilance database, disproportionality of movement disorders’ reporting was assessed among adverse drug reactions related to any antidepressant, from January 1967 to February 2017, through a case/non-case design. The association between nine subtypes of movement disorders (akathisia, bruxism, dystonia, myoclonus, parkinsonism, restless legs syndrome, tardive dyskinesia, tics, tremor) and antidepressants was estimated through the calculation first of crude Reporting Odds Ratio (ROR), then adjusted ROR on four potential confounding factors: age, sex, drugs described as able to induce movement disorders, and drugs used to treat movement disorders. Results: Out of the 14,270,446 reports included in VigiBase®, 1,027,405 (7.2%) contained at least one antidepressant, among whom 29,253 (2.8%) reported movement disorders. The female/male sex ratio was 2.15 and the mean age 50.9 ± 18.0 years. We found a significant increased ROR for antidepressants in general for all subtypes of movement disorders, with the highest association with bruxism (ROR 10.37, 95% CI 9.62–11.17) and the lowest with tics (ROR 1.49, 95% CI 1.38–1.60). When comparing each of the classes of antidepressants with the others, a significant association was observed for all subtypes of movement disorders except restless legs syndrome with serotonin reuptake inhibitors (SRIs) only. Among antidepressants, mirtazapine, vortioxetine, amoxapine, phenelzine, tryptophan and fluvoxamine were associated with the highest level to movement disorders and citalopram, paroxetine, duloxetine and mirtazapine were the most frequently associated with movement disorders. An association was also found with eight other antidepressants. Conclusions: A potential harmful association was found between movement disorders and use of the antidepressants mirtazapine, vortioxetine, amoxapine, phenelzine, tryptophan, fluvoxamine, citalopram, paroxetine, duloxetine, bupropion, clomipramine, escitalopram, fluoxetine, mianserin, sertraline, venlafaxine and vilazodone. Clinicians should beware of these adverse effects and monitor early warning signs carefully. However, this observational study must be interpreted as an exploratory analysis, and these results should be refined by future epidemiological studies.

30 September 2016 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
TNThi Thu Ha Nguyen
Thi Thu Ha Nguyen
APAntoine Pariente
Antoine Pariente
JMJean‐Louis Montastruc
Jean‐Louis Montastruc
MLMaryse Lapeyre-Mestre
Maryse Lapeyre-Mestre
VRVanessa Rousseau
Vanessa Rousseau
FMFrançois Montastruc
François Montastruc
Aims: Pharmacovigilance databases are usually used to detect new potential signals that are relevant for drug safety. They are seldom used for explanatory purposes, e.g. to understand the mechanisms of adverse drug reactions (ADRs). The aim of the present study was to combine pharmacovigilance and pharmacodynamic data to investigate the association between dopamine D2, serotonin 5HT2A, and muscarinic M1 receptor occupancy and the risks of antipsychotic drug (AP)‐induced movement disorders.Methods: First, we performed a case–noncase analysis using spontaneous reports from the World Health Organization (WHO) Global Individual Case Safety Report (ICSR) database, VigiBase®. We thus measured the risk of reporting movement disorders compared with all other ADRs [expressed as a reporting odds ratio (ROR)] for APs. Second, we performed a linear regression analysis to explore the association between the estimated risk of reporting for individual drugs and their receptor occupancy properties, for D2, 5HT2A and M1 receptors.Results: Compared with second‐generation APs, first‐generation APs were found to be significantly more associated with the reporting of movement disorders in general but also with dystonia, Parkinsonism, akathisia and tardive dyskinesia, irrespective of gender. A significant inverse correlation was found between the ROR for movement disorders and the receptor occupancy of 5HT2A [P < 0.001; R2 = 0.51; slope = −0.014; 95% confidence interval (CI) (−0.029, 0.001)], M1 (P < 0.001; R2 = 0.56; slope = −0.014; 95% CI (−0.028, 0.001) but not D2 dopamine (P = 0.54; R2 = 0.02; slope = −0.003; 95% CI (−0.007, 0.001) receptors.Conclusions: Using the example of AP‐induced movement disorders, the present study underlines the value of the pharmacoepidemiological–pharmacodynamic method to explore ADR mechanisms in humans and real‐life settings.

23 November 2022 in Brain
Verified
Journal Article
Open access
PDF file
GPGiancarlo Pesce
Giancarlo Pesce
FAFanny Artaud
Fanny Artaud
EREmmanuel Roze
Emmanuel Roze
IDIsabelle Degaey
Isabelle Degaey
BPBerta Portugal
Berta Portugal
MCMarianne Canonico
Marianne Canonico
Despite experimental studies suggesting a disease-modifying role of oestrogens, results from epidemiological studies on the relation of reproductive characteristics and hormonal exposures with Parkinson disease in women are conflicting. We used the data from the E3N cohort study including 98 068 women aged 40–65 years in 1990 followed until 2018. Parkinson disease was ascertained using a validation process based on drug claim databases and medical records. Reproductive characteristics and hormonal exposures were self-reported (11 questionnaires). Associations of exposures with Parkinson disease incidence were investigated using time-varying Cox proportional hazards regression with a 5-year exposure lag and age as the timescale adjusted for confounders. We identified 1165 incident Parkinson disease cases during a mean follow-up of 22.0 years (incidence rate = 54.7 per 100 000 person-years). Parkinson disease incidence was higher in women with early (<12 years, HR = 1.21, 95% CI = 1.04–1.40) or late age at menarche (≥14 years, HR = 1.18, 95% CI = 1.03–1.35) than in women with menarche at 12–13 years. Nulliparity was not associated with Parkinson disease, but Parkinson disease incidence increased with the number of children in parous women (P-trend = 0.009). Women with artificial (surgical, iatrogenic) menopause were at greater risk than women with natural menopause (HR = 1.28, 95% CI = 1.09–1.47), especially when artificial menopause occurred at an early age (≤45.0 years). Postmenopausal hormone therapy tended to mitigate greater risk associated with artificial or early menopause (≤45.0 years). While fertility treatments were not associated with Parkinson disease overall, ever users of clomiphene were at greater Parkinson disease risk than never users (HR = 1.81, 95% CI = 1.14–2.88). Other exposures (breastfeeding, oral contraceptives) were not associated with Parkinson disease. Our findings suggest that early and late age at menarche, higher parity, and artificial menopause, in particular at an early age, are associated with increased Parkinson disease incidence in women. In addition, there was some evidence that use of exogenous hormones may increase (fertility treatments) or decrease (postmenopausal hormone therapy) Parkinson disease incidence. These findings support the hypothesis that hormonal exposures play a role in the susceptibility to neurodegenerative diseases. If confirmed, they could help to identify subgroups at high risk for Parkinson disease.

14 February 2023 in Movement Disorders
Verified
Journal Article
Open access
TNThi Thu Ha Nguyen
Thi Thu Ha Nguyen
AFAgnès Fournier
Agnès Fournier
ÉCÉmeline Courtois
Émeline Courtois
FAFanny Artaud
Fanny Artaud
SESylvie Escolano
Sylvie Escolano
AEAlexis Elbaz
Alexis Elbaz
Background: Statins represent candidates for drug repurposing in Parkinson's disease (PD). Few studies examined the role of reverse causation, statin subgroups, and dose–response relations based on time‐varying exposures.Objectives: We examined whether statin use is associated with PD incidence while attempting to overcome the limitations described previously, especially reverse causation.Method: We used data from the E3N cohort study of French women (follow‐up, 2004–2018). Incident PD was ascertained using multiple sources and validated by experts. New statin users were identified through linked drug claims. We set up a nested case‐control study to describe trajectories of statin prescriptions and medical consultations before diagnosis. We used time‐varying multivariable Cox proportional hazards regression models to examine the statins–PD association. Exposure indexes included ever use, cumulative duration/dose, and mean daily dose and were lagged by 5 years to address reverse causation.Results: The case‐control study (693 cases, 13,784 controls) showed differences in case‐control trajectories, with changes in the 5 years before diagnosis in cases. Of 73,925 women (aged 54–79 years), 524 developed PD and 11,552 started using statins in lagged analyses. Ever use of any statin was not associated with PD (hazard ratio [HR] = 0.87, 95% confidence interval [CI] = 0.67–1.11). Alternatively, ever use of lipophilic statins was significantly associated with lower PD incidence (HR = 0.70, 95% CI = 0.51–0.98), with a dose–response relation for the mean daily dose (P‐linear trend = 0.02). There was no association for hydrophilic statins.Conclusion: Use of lipophilic statins at least 5 years earlier was associated with reduced PD incidence in women, with a dose–response relation for the mean daily dose. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

25 January 2017 in Journal of International Medical Research
Verified
Journal Article
Open access
HDHuong Duong-Thi-Ly
Huong Duong-Thi-Ly
HNHa Nguyen-Thi-Thu
Ha Nguyen-Thi-Thu
LNLong Nguyen-Hoang
Long Nguyen-Hoang
HNHanh Nguyen-Thi-Bich
Hanh Nguyen-Thi-Bich
TCTimothy J. Craig
Timothy J. Craig
Sy Duong-QuySy Duong-Quy
Sy Duong-Quy
Numerous studies have examined the association between pharmacogenetic effects and the response to inhaled corticosteroids (ICS) in patients with asthma. In fact, several single nucleotide polymorphisms of a number of candidate genes have been identified that might influence the clinical response to ICS in children with asthma. Their direct or indirect effects depend on their role in the inflammatory process in asthma or the anti-inflammatory action of corticosteroids, respectively. Among the genes identified, variants in T-box 21 (TBX21) and Fc fragment of IgE receptor II (FCER2) contribute indirectly to the variability in the response to ICS by altering the inflammatory mechanisms in asthma, while other genes such as corticotropin releasing hormone receptor 1 (CRHR1), nuclear receptor subfamily 3 group C member 1 (NR3C1), stress induced phosphoprotein 1 (STIP1), dual specificity phosphatase 1 (DUSP1), glucocorticoid induced 1 (GLCCI1), histone deacetylase 1 (HDAC), ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3), and vascular endothelial growth factors (VEGF) directly affect this variability through the anti-inflammatory mechanisms of ICS. The results to date indicate various potential genetic factors associated with the response to ICS, which could be utilized to predict the individual therapeutic response of children with asthma to ICS. Clinical trials are underway and their results are greatly anticipated. Further pharmacogenetic studies are needed to fully understand the effects of genetic variation on the response to ICS in children with asthma.

28 June 2018 in Drug Safety
Verified
Journal Article
Closed access
PDF file
TNThi Thu Ha Nguyen
Thi Thu Ha Nguyen
ARAnne Roussin
Anne Roussin
VRVanessa Rousseau
Vanessa Rousseau
JMJean-Louis Montastruc
Jean-Louis Montastruc
FMFrançois Montastruc
François Montastruc